CA-YOU.COM
6.3.2024 02:17:34 CET | Business Wire | Press release
You.com announces its designation as one of the few new default browser options on iOS 17.4 for European Union users, alongside significant updates to its AI-powered mobile browsing app, You.com AI Search and Browse.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240305667601/en/
Newly Revamped You.com AI Search and Browse App Now Available on iOS 17.4 in the European Union as Part of New Browser Choice Screen (Graphic: Business Wire)
The inclusion in the iOS browser choice screen today highlights You.com's increasing global popularity and dedication to delivering a cutting-edge AI-powered web search and browsing experience loved by its users.
“We're excited to share the latest update to our You.com AI Search and Browse app, now available as a default browser choice on iOS 17.4 for users throughout the European Union. As the only AI chat-native browser option on the new EU browser choice screen for iOS, You.com is setting a new standard for what a browser can do thanks to AI,” said Richard Socher, CEO of You.com.
Socher continued: “With the introduction of 'Ask AI' and a fresh, intuitive app design, we're not just updating features, we're enhancing how you find information online. You.com is more than another way to search and browse — it's an AI Assistant designed to make you more productive, creative, and extraordinary. We invite you to make You.com your default browser for a smarter way to find answers.”
What’s new:
- Introducing “Ask AI”: Dive into the future of search with our new "Ask AI" feature, delivering AI-powered answers complete with citations for a more informative and trustworthy browsing experience.
- A fresh, updated experience: Enjoy a cleaner, more intuitive interface with our updated app design, making navigation smoother and more enjoyable than ever before.
- Enhanced mobile homepage: Discover what's trending with an improved mobile home page that now offers trending suggestions, keeping you informed and engaged with the latest and most relevant content.
With You.com, users can say goodbye to endless scrolling through blue links and tedious websites. Search alone is inefficient for in-depth research, and ineffective at answering complex, multi-step questions. A conversational search experience powered by cutting-edge AI, You.com delivers immediate, comprehensive answers across any topic, supplemented by follow-up suggestions for deeper exploration.
You.com enhances the efficiency of finding information and enriches the quality of results with advanced AI functionalities that support text generation, content summarization, image creation, and more. You.com stands out for its powerful AI Modes, from its Research Mode which can browse and synthesize information from multiple websites simultaneously with extensive citations to its Genius Mode capable of multi-step complex problem solving.
Whether users prefer traditional search methods or the enriched, AI-enhanced search, You.com offers seamless management of searches, chats, and visited websites, with easy options for saving or deleting history. Linked citations further empower users to verify responses and delve into sources, ensuring a trustworthy and comprehensive browsing experience.
You.com also prioritizes privacy, offering ad-blocking, pop-up blocking, and tracking protection capabilities.
Download You.com today for free and experience a better way to search.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240305667601/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
KATE Launches "KABUKE: Break Convention" Kabuki-Inspired International Campaign17.7.2026 09:00:00 CEST | Press release
Where “NO MORE RULES.” intersects with the Kabuku spirit. Inspired by Japanese aesthetics, KATE shares the value of shadow enhancing makeup and self‑expression with the world. Global cosmetics brand KATE launched “KABUKE: Break Convention,” a new international campaign drawing on elements of Kabuki, the traditional Japanese performing art. The campaign debuted on Wednesday, July 8, 2026. In this campaign, KATE’s shadow enhancing makeup—rooted in Japanese aesthetics—was paired with the Kabuki spirit inherited from traditional Kabuki theater to communicate the value of individuality and self‑expression through makeup on a global scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708829427/en/ KATE international campaign “KABUKE: Break Convention” key visual. Dedicated website: https://www.kate-global.net/my/special/kate_kabuki/ Since its founding, KATE has championed the slogan “NO MORE RULES.,” offering makeup that defi
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe’s Coverage of ESCMID Global Congress 202617.7.2026 03:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 03:00:00 CEST | Press release
Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 00:00:00 CEST | Press release
On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 Approximately 70% of patients with palmoplantar disease treated with zasocitinib achieved clear or almost clear skin at week 16 Zasocitinib demonstrated statistically significant improvements in Nail Psoriasis Severity Index (NAPSI) versus placebo Results reinforce the potential of zasocitinib to deliver rapid and durable skin clearance, including in the hardest-to-treat areas, in a convenient once-daily pill Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-
Merz Completes Inaugural €450 Million Schuldschein Loan Issuance16.7.2026 23:36:00 CEST | Press release
Debut transaction more than three times oversubscribed The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful plac
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom